KL and Alzheimer disease: For instance, a longitudinal study in 2020 suggested that increased serum level of Klotho (in Klotho‐VS heterozygous individuals) is associated with reduced AD risk in APOE4 carriers from 60 to 80 years of age (Belloy et al., 2020).